These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 29475177)

  • 1. Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban.
    Verdoia M; Pergolini P; Barbieri L; Rolla R; Nardin M; Negro F; Suryapranata H; De Luca G;
    Thromb Res; 2018 Apr; 164():17-23. PubMed ID: 29475177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
    Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting.
    Verdoia M; Schaffer A; Barbieri L; Cassetti E; Di Giovine G; Marino P; De Luca G;
    J Cardiovasc Med (Hagerstown); 2015 Feb; 16(2):100-5. PubMed ID: 24625566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive loading dose of cilostazol in preventing periprocedural myocardial infarction.
    Xu LX; Chen KY; Liu T; Zheng XT; Jiao ZQ; Xu Y; Li G
    Cardiovasc Ther; 2016 Aug; 34(4):225-33. PubMed ID: 27133311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet distribution width and the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention.
    Verdoia M; Barbieri L; Schaffer A; Cassetti E; Di Giovine G; Bellomo G; Marino P; Sinigaglia F; De Luca G
    J Thromb Thrombolysis; 2014 Apr; 37(3):345-52. PubMed ID: 23793523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
    J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet HPA-1 a/HPA-1 b polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI.
    Verdoia M; Secco GG; Barbieri L; Cassetti E; Schaffer A; Sinigaglia F; Marino P; Suryapranata H; De Luca G;
    Platelets; 2014; 25(5):367-72. PubMed ID: 24283589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients with acute coronary syndromes undergoing coronary angioplasty.
    Verdoia M; Secco GG; Cassetti E; Schaffer A; Barbieri L; Perrone-Filardi P; Marino P; Suryapranata H; Sinigaglia F; De Luca G
    Blood Coagul Fibrinolysis; 2014 Mar; 25(2):107-13. PubMed ID: 24480844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
    Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Hermanides RS; van Werkum JW; Ottervanger JP; Breet NJ; Gosselink AT; van Houwelingen KG; Dambrink JH; Hamm C; ten Berg JM; van 't Hof AW;
    Catheter Cardiovasc Interv; 2012 May; 79(6):956-64. PubMed ID: 22162050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; Luca GD;
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):143-50. PubMed ID: 26868495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Polymorphism rs5751876 of the Purinergic Receptor ADORA2A on Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention.
    Negro F; Verdoia M; Nardin M; Suryapranata H; Kedhi E; Dudek D; De Luca G;
    J Atheroscler Thromb; 2021 Feb; 28(2):137-145. PubMed ID: 33342966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
    Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eosinophils count and periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions.
    Verdoia M; Schaffer A; Barbieri L; Sinigaglia F; Marino P; Suryapranata H; De Luca G;
    Atherosclerosis; 2014 Sep; 236(1):169-74. PubMed ID: 25055060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.